Our Team
Directors
President
Marni Warren is the proud parent of Luke (20) and Mary Nell (18). In 2013 Mary Nell (age 5) began to have absence and myoclonic seizures and thus began the journey to find out the cause. After no conclusion from the Epilepsy Genetic Panel she and her husband, Mark, began their campaign for answers. They scoured the country seeing specialists at Duke University Hospital, NYU, National Jewish Hospital and even sought out biomedical, neutrogenomic and homeopathic solutions. Finally, after whole exome sequencing they got her diagnosis of CHD2 mutation and were told that it was rare and no protocols for treatment existed. Although it was their worst fear they at least had information and could then find the CHD2 community for support and furthering the cause for a cure. Marni is a strong proponent of looking beyond “symptom based” solutions to neurological abnormalities and advancing a comprehensive genetic approach to complex disorders like CHD2.
Marni currently stays home with her children but has a background in Finance and Strategic Planning working with Bank of America Securities, CoBank and Johns Manville Corporate Development. She has her BA from Miami University in Ohio and MBA from University of Denver. She has served on various boards including Epilepsy Foundation of Colorado, YMCA, Junior League of Denver, her local school and church. Marni resides in Greenwood Village CO.
Secretary
Mike Fasolo joins the board, sharing his passion for working to help improve the lives of those affected by the CHD2 mutation, and for the hope of one day finding a cure. Mike and his wife Lauren live in the suburbs of Chicago, and are the loving parents of a teenager who has been diagnosed with the CHD2 mutation and hope to help in any way they can. He previously has served on the board of the Center for Speech and Language Disorders, a Lisle, IL based non-profit focused on helping children with language and other developmental disorders. In his professional life, Mike is currently in an operations leadership role at Amazon, and has previously worked in a variety of leadership roles at Brunswick Corporation, Starwood Hotels, and Ford Motor Company
Treasurer
Chris has a son who is affected by the CHD2 gene mutation. Along with his wife, Elizabeth, Chris has been on a journey to understand the impact of this condition and give their son everything possible to help overcome its debilitating symptoms. The CHD2 family community has been a source of strength and hope, and as a founding member of CCC, Chris is determined to help advance research in the field with the goal of developing targeted treatments for the disease.
Chris works for Legal and General Investment Management in Chicago. He has a BS in Software Engineering from Fairfield University and a MBA from the University of Chicago Booth School of Business. Chris, Elizabeth and their two children reside in Chicago and are active members of various city and neighborhood organizations.
Board Member
Dean Aguiar joined the CCC Board in 2026. He is the Vice President, Translational Research at the TSC Alliance, where he has worked since 2018, following more than 17 years of research and development (R&D) leadership in biopharmaceutical and medical research industries, leading teams and technologies from discovery to investigational new drug (IND) and investigational device exemption (IDE), a pre-requisite for clinical trial evaluation. He brings an entrepreneurial and collaborative approach to R&D, identifying opportunity, defining strategy and developing a scientific data package to warrant clinical translation of technologies to benefit the patient, the family and care provider. In his prior role as Program Director at The Hartwell Foundation, he gained significant experience in pediatric disease from oncology and inflammation to neurodevelopmental disorders including autism, ADHD and epilepsy. He provided guidance to academic investigators regarding the scientific evidence and regulatory path required to successfully translate technologies toward commercial viability. He also established partnerships with industry to gain access to proprietary drugs and a possible path for licensing.
He cofounded Pendant Biosciences, a Johnson & Johnson Innovation JLABS company, with a mission to develop a novel polymer biomaterial for targeted drug delivery improving efficacy and minimizing toxicity. He contributed to the leadership team that identified opportunities for the company’s core technology to address unmet patient needs and was responsible for developing an R&D strategy and data package to attract strategic partners. In addition, He has a breadth of pharmaceutical R&D experiences from early discovery to clinical translation that provides a unique perspective on project management and mitigating risk. As the former Director of Product Development at Biomimetic Therapeutics, a medical device company, he led a team focused on the development of drug-device combination products and drug-only products bridging the regulatory framework for a drug and a device. His early career landed him at Pfizer, where he led cross-functional project teams in the areas of inflammation spanning discovery to preclinical development of both small molecules and protein biologic drugs. He played a key role while ensuring a robust decision funnel for translatable cell, animal models and biomarkers of human disease.
Dean earned his PhD in Biochemistry from Rush University at Rush Presbyterian St. Luke’s Medical Center and completed post-doctoral training at the University of Minnesota. He and his wife, Missie, have three boys – Ryan, Cole and Chase.
Board Member
Stephanie and her husband James have a daughter with a CHD2 pathological variant. She was diagnosed in January 2021 aged 4 during the Covid-19 pandemic after presenting with myoclonic seizures. Her daughter is the eldest of three children.
Stephanie is a UK Clinical Oncologist. In her role for CCC she hopes to combine her parent and medical knowledge to assist CCC in reaching out to academics and pharmaceutical companies to establish more research into CHD2. She believes our future research directions include understanding how this gene causes neurodevelopmental disorders, other genes/proteins that influence the function of CHD2 and ultimately lead to targeted treatments to improve seizure control and associated neurodevelopmental complications.
Board Member
Justin Schueler’s daughter was diagnosed with CHD2 myoclonic encephalopathy in March 2023 at 18 months old. Being thrown into the rare disease world was shocking and left him and his wife Nicole feeling lost as parents.
Finding CCC has been incredibly uplifting and provided opportunities to connect with other CHD2 families, speak to researchers in the scientific community, and align our combined efforts to FIND A CURE. Professionally, Justin is a civil engineer working as a project manager in the transportation field. His work focuses on traffic operations, safety analysis, multimodal facilities, roadway improvement projects, and private developments.
After attending the inaugural CHD2 Family and Scientific conference in 2023, Justin wanted to find a way to help advance the community and spread awareness to other newly diagnosed families. Using his past experience planning engineering conferences, he has joined efforts with Marni Warren to co-chair the 2025 CCC conference.
Justin resides in Milwaukee, Wisconsin with his wife Nicole, son (5) and daughter (3). In his free time, he enjoys traveling, camping in the summer, spending time with his family, working on home remodeling projects, and following the local sports teams.
Board Member
Madison Wharton joined the Coalition to Cure CHD2 board in 2025 to help the organization's communications efforts. As the mother of Violet, who was diagnosed with CHD2, Madison has experienced firsthand the challenges and uncertainties that come with this rare genetic condition—and she's seen the incredible strength and resilience of the CHD2 community. She's committed to amplifying the voices of families affected by CHD2, raising awareness, and working toward the day when effective treatments and a cure become a reality.
Madison brings over 20 years of experience in strategic communications and creative leadership to the Coalition. As Chief Operating Officer of Residence, a network of eight creative companies, she leads collaboration and innovation across teams that work with brands like Apple, Google, and Microsoft. Throughout her career at agencies including BUCK, DDB, and The Barbarian Group, Madison has built award-winning campaigns and led high-performing teams. She's passionate about bringing her communications expertise to the CHD2 community, helping connect families, researchers, and advocates as we work together to change the trajectory of this disease. Madison lives in Savannah with her husband, Jason, and their two children, Virgil and Violet.
Co-Founder and Honorary Board Member
In April 2010, Lauren and her husband John welcomed triplet girls to their family and their dreams of starting a family came true instantly. Two and half years later, one of their daughters experienced her first seizure. For six years, Lauren had her daughter go on a diagnostic odyssey taking every possible test, seeing numerous physicians and flying her to multiple states where they searched for a diagnosis and cause for her daughter’s Epilepsy and developmental delays.
In December of 2018, they finally learned through an Epilepsy Gene panel that she had a spontaneous mutation of the CHD2 gene. With the diagnosis came a lot of unanswered questions, lack of resources and guidance on medication options. The diagnosis led Lauren to a patient and caregiver community but still offered no real answers to fix her daughter's symptoms. Lauren decided to take matters into her own hands. In late 2020, she called Christine Salmi, another mom who has a daughter with a CHD2 mutation and they decided together, they were going to build a non-profit whose main goal would be to fund research in order to find a CURE for CHD2 neurodevelopmental disorders.
Lauren has spent her entire professional career communicating with physicians in the pharmaceutical and medical device space. It wasn’t until 2017 though, where her connection between her personal life and her professional life found the ultimate synergy. Lauren is currently a Regional Sales Manager for Jazz Pharmaceuticals. Lauren lives in Arizona and has previously served as the President and Vice-President of Seville Golf & Country Club’s Board of Governors. She also has volunteered as a Seizure Smart Trainer for the Epilepsy Foundation of Arizona. She received her B.A. in Communications from Rowan University.
Honorary Board Member
Christina SanInocencio has been involved in rare epilepsy advocacy and non-profit management for 15 years. She is the founder and former executive director of the LGS Foundation and has a 35 year old brother living with Lennox-Gastaut Syndrome. Dr. SanInocencio's research interests include interpersonal health communication, health literacy, medical transitioning, and social support. She currently holds academic appointments at Fairfield University and Stony Brook University and serves as a rare disease / non-profit consultant and qualitative researcher.
​Christina resides in Long Island, New York
Staff
Executive Director
Laura Marks joined Coalition to Cure CHD2 in November 2023 as its first Executive Director. An expert in nonprofit management and administration focusing on international development and human rights, she has led the NY Community Center for Women for Afghan Women; Louis and Nancy Hatch Dupree Foundation for the Afghanistan Centre at Kabul University; and Columbia Law School’s Human Rights Institute.
Laura has extensive lived experience with many challenges faced by families affected by developmental and epileptic encephalopathies: Her older sister has epilepsy, intellectual disability, autism and schizophrenia caused by a SYNGAP1* genetic mutation. Laura was a young child when her parents were among the first to successfully sue the state of Connecticut for private education services under the Education for All Handicapped Children Act (later replaced by the Individuals with Disabilities Education Act). More than 30 years later, Laura's younger son was diagnosed with tuberous sclerosis complex caused by a change in his TSC2** gene. As a result, Laura became a highly committed volunteer leader for the TSC community and staunch advocate for appropriate education for all students with disabilities, including those with high academic potential. In 2023 she pivoted away from human rights to focus full-time on improving the lives of people affected by rare genetic epilepsy.
Laura serves on the Board of Directors of the TSC Alliance and as chair of its Global Relations Committee. She is co-lead of the TSC Alliance Community of NY, NJ & CT. She earned her undergraduate degree from Columbia University and a master’s degree from Columbia University's School of International and Public Affairs.
She and her husband live in Queens, New York and are the parents of two young adults. She can be reached at laura [at] curechd2.org
* Like CHD2, SYNGAP1 mutations are ultra rare and cause developmental and epileptic encephalopathy (DEE)
** TSC is a rare genetic disease that causes non-cancerous tumors to form in vital organs, and is associated with epilepsy, autism, and intellectual disability.